Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,854 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, Accordino M, Crew KD, Hershman DL, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Zeleke TZ, et al. Among authors: silva j. Nat Cancer. 2023 Feb;4(2):257-275. doi: 10.1038/s43018-022-00489-5. Epub 2022 Dec 30. Nat Cancer. 2023. PMID: 36585452 Free PMC article.
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J. Putcha P, et al. Among authors: silva j. Breast Cancer Res. 2015 Dec 8;17(1):149. doi: 10.1186/s13058-015-0658-0. Breast Cancer Res. 2015. PMID: 26643555 Free PMC article.
Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J. Putcha P, et al. Among authors: silva j. Breast Cancer Res. 2017 Apr 19;19(1):49. doi: 10.1186/s13058-017-0841-6. Breast Cancer Res. 2017. PMID: 28424080 Free PMC article. No abstract available.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Kearney M, Franks L, Lee S, Tiersten A, Makower DF, Cigler T, Mundi P, Chi DC, Goel A, Klein P, Andreopoulou E, Sparano J, Trivedi M, Accordino M, Califano A, Hershman DL, Silva J, Kalinsky K. Kearney M, et al. Among authors: silva j. Breast Cancer Res Treat. 2021 Aug;189(1):177-185. doi: 10.1007/s10549-021-06306-4. Epub 2021 Jun 24. Breast Cancer Res Treat. 2021. PMID: 34169393 Free PMC article. Clinical Trial.
SEC14L2 enables pan-genotype HCV replication in cell culture.
Saeed M, Andreo U, Chung HY, Espiritu C, Branch AD, Silva JM, Rice CM. Saeed M, et al. Nature. 2015 Aug 27;524(7566):471-5. doi: 10.1038/nature14899. Epub 2015 Aug 12. Nature. 2015. PMID: 26266980 Free PMC article.
An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy.
Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre-Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, Skinner HD, de Stanchina E, Sidi S. Liu PH, et al. Nat Cell Biol. 2019 Feb;21(2):203-213. doi: 10.1038/s41556-018-0260-7. Epub 2019 Jan 21. Nat Cell Biol. 2019. PMID: 30664786 Free PMC article.
12,854 results
You have reached the last available page of results. Please see the User Guide for more information.